Literature DB >> 160558

Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.

R G Moran, M Mulkins, C Heidelberger.   

Abstract

Methotrexate (MTX) inhibition of the growth of mouse or human leukemia cells in culture was partially prevented by either thymidine (dThd) or hypoxanthine. 5-Fluoro-2'-deoxyuridine (FdUrd) also decreased the growth-inhibitory potency of MTX in the presence of small concentrations of 5-formyltetrahydrofolate (citrovorum factor) and sufficient exogenous dThd to support the synthesis of thymidylate nucleotides by salvage mechanisms. In addition, citrovorum factor-induced reversal of MTX was several orders of magnitude more efficient in the presence of both FdUrd and dThd than in the presence of dThd alone or in the absence of both nucleosides. Likewise, the presence of FdUrd (3 microM) and dThd (5.6 microM) completely prevented the lethality of 0.3 mM MTX to L1210 cells in culture medium supplemented with micromolar concentrations of citrovorum factor. We propose that this protection against the cytotoxic effects of MTX by dThd, hypoxanthine, and FdUrd have a common biochemical mechanism--namely, inhibition of the de novo synthesis of thymidylate by either a direct [FdUrd; inhibition of thymidylate synthetase (thymidylate synthase; 5,10-methylenetetrahydrofolate:dUMP C-methyl-transferase, EC 2.1.1.45)] or indirect (dThd and hypoxanthine; feedback inhibition by anabolites on ribonucleotide reductase and deoxycytidylate deaminase) effect. The resultant decreased rate of loss of reduced folates due to de novo thymidylate synthesis would allow a higher degree of inhibition of dihydrofolate reductase to be endured without damage to the cell.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 160558      PMCID: PMC411765          DOI: 10.1073/pnas.76.11.5924

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Mechanism of growth inhibition by methotrexate.

Authors:  M W McBurney; G F Whitmore
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

2.  Effects of allopurinol on the therapeutic efficacy of methotrexate.

Authors:  G B Grindey; R G Moran
Journal:  Cancer Res       Date:  1975-07       Impact factor: 12.701

3.  The ability of purine and thymine derivatives and of glycine to support the growth of mammalian cells in culture.

Authors:  M T HAKALA; E TAYLOR
Journal:  J Biol Chem       Date:  1959-01       Impact factor: 5.157

4.  Prevention of toxicity of amethopterin for sarcoma-180 cells in tissue culture.

Authors:  M T HAKALA
Journal:  Science       Date:  1957-08-09       Impact factor: 47.728

5.  The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects.

Authors:  M H Tattersall; B Brown; E Frei
Journal:  Nature       Date:  1975-01-17       Impact factor: 49.962

6.  Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells.

Authors:  D Niethammer; R C Jackson
Journal:  Eur J Cancer       Date:  1975-12       Impact factor: 9.162

7.  Methotrexate inhibition of CCRF-CEM cultures of human lymphoblasts.

Authors:  D Roberts; E V Warmath
Journal:  Eur J Cancer       Date:  1975-11       Impact factor: 9.162

8.  The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides.

Authors:  H M Pinedo; D S Zaharko; J M Bull; B A Chabner
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

9.  Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase.

Authors:  R G Moran; C P Spears; C Heidelberger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

10.  Methotrexate and the need for continued research.

Authors:  F Rosenfelt
Journal:  Yale J Biol Med       Date:  1975-05
View more
  18 in total

1.  Mitochondrial One-Carbon Pathway Supports Cytosolic Folate Integrity in Cancer Cells.

Authors:  Yuxiang Zheng; Ting-Yu Lin; Gina Lee; Marcia N Paddock; Jessica Momb; Zhe Cheng; Qian Li; Dennis L Fei; Benjamin D Stein; Shivan Ramsamooj; Guoan Zhang; John Blenis; Lewis C Cantley
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

2.  A study of deoxyribonucleotide metabolism and its relation to DNA synthesis. Supercomputer simulation and model-system analysis.

Authors:  F Heinmets; R H Leary
Journal:  Cell Biophys       Date:  1991-06

3.  Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage.

Authors:  T G Paulson; A Almasan; L L Brody; G M Wahl
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

4.  5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates.

Authors:  D J Fernandes; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

5.  Differential calcium leucovorin protection of human lymphoid cell lines from methotrexate.

Authors:  G P Browman; L Booker; P Spiegl
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Kinetic behaviour and allosteric regulation of human deoxycytidylate deaminase derived from leukemic cells.

Authors:  P H Ellims; A Y Kao; B A Chabner
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

7.  Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil.

Authors:  L L Danhauser; R Heimer; E Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 8.  Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.

Authors:  P H Ellims
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

9.  Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate.

Authors:  G A Curt; J Jolivet; D N Carney; B D Bailey; J C Drake; N J Clendeninn; B A Chabner
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

10.  Construction of a dihydrofolate reductase-deficient mutant of Escherichia coli by gene replacement.

Authors:  E E Howell; P G Foster; L M Foster
Journal:  J Bacteriol       Date:  1988-07       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.